Wegovy®
Wegovy contains semaglutide, a GLP-1 receptor agonist. It's authorised for weight management in eligible patients alongside a reduced-calorie diet and more physical activity.
- Usually injected once a week, following the instructions you're given.
- The dose is normally increased gradually to help your body adjust.
- Common side effects include nausea, vomiting, diarrhoea and constipation.
Your prescriber reviews your medical history, other medicines, relevant risks and the current UK product information before deciding whether it's suitable.
Read the official UK medicine information